TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07412691: A Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of BG-A3004 in Healthy Participants and Patients

Sponsor: BeOne Medicines · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 98 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,315,808

Rescue Site Savings

+$1,526,328

Unlock Full NCT07412691 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07412691 Rescue Dossier →